| 177.47 -2.88 (-1.6%) | 09-04 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 213.11 |
1-year : | 223.81 |
| Resists | First : | 182.45 |
Second : | 191.61 |
| Pivot price | 182.13 |
|||
| Supports | First : | 167.63 |
Second : | 139.47 |
| MAs | MA(5) : | 178.72 |
MA(20) : | 182.8 |
| MA(100) : | 146.99  |
MA(250) : | 120.27 |
|
| MACD | MACD : | 3.3 |
Signal : | 5.3 |
| %K %D | K(14,3) : | 27.8 |
D(3) : | 26.4 |
| RSI | RSI(14): 51.9 |
|||
| 52-week | High : | 191.61 | Low : | 73.16 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ GKOS ] has closed above bottom band by 15.8%. Bollinger Bands are 52.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 181.46 - 182.51 | 182.51 - 183.45 |
| Low: | 172.78 - 173.89 | 173.89 - 174.9 |
| Close: | 175.85 - 177.66 | 177.66 - 179.29 |
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
Fri, 04 Sep 2026
Stifel Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $190 - Moomoo
Thu, 03 Sep 2026
Chief Development Officer Of Glaukos Sold 28% Of Their Shares - simplywall.st
Tue, 01 Sep 2026
Glaukos chief development officer sells $2.48m in shares - Investing.com
Mon, 31 Aug 2026
Glaukos Corporation (GKOS) Growth Potential: A Healthcare Innovator With A 9.61% Upside - DirectorsTalk Interviews
Thu, 20 Aug 2026
GKOS Stock Surges 67% Year to Date: What's Driving the Rally? - Eastern Progress
Wed, 19 Aug 2026
Glaukos Announces Participation in Wells Fargo Healthcare Conference - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 59 (M) |
| Shares Float | 57 (M) |
| Held by Insiders | 3.5 (%) |
| Held by Institutions | 105.4 (%) |
| Shares Short | 3,950 (K) |
| Shares Short P.Month | 4,700 (K) |
| EPS | -3.27 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.6 |
| Profit Margin | -30.7 % |
| Operating Margin | -8.5 % |
| Return on Assets (ttm) | -5.2 % |
| Return on Equity (ttm) | -26 % |
| Qtrly Rev. Growth | 49.5 % |
| Gross Profit (p.s.) | 8.22 |
| Sales Per Share | 10.39 |
| EBITDA (p.s.) | -0.63 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1 (M) |
| Levered Free Cash Flow | 15 (M) |
| PE Ratio | -54.28 |
| PEG Ratio | 0 |
| Price to Book value | 15.29 |
| Price to Sales | 17.07 |
| Price to Cash Flow | -11018.1 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|